These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8728346)

  • 1. Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers.
    Vashi V; Chung M; Dias N; Phillips K
    J Clin Pharmacol; 1996 Apr; 36(4):325-31. PubMed ID: 8728346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence evaluation of two formulations of doxazosin tablet in healthy thai male volunteers.
    Sripalakit P; Nermhom P; Maphanta S; Polnok S; Jianmongkol P; Saraphanchotiwitthaya A
    Drug Dev Ind Pharm; 2005 Dec; 31(10):1035-40. PubMed ID: 16316859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers.
    Ma N; Liu W; Li H; Chen B; Zhu Y; Liu X; Wang F; Xiang D; Zhang B
    J Pharm Biomed Anal; 2007 Feb; 43(3):1049-56. PubMed ID: 17055685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers.
    Kwon YH; Gwak HS; Yoon SJ; Chun IK
    Drug Dev Ind Pharm; 2007 Aug; 33(8):824-9. PubMed ID: 17729099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
    Kirby RS
    Int J Clin Pract; 1998 Mar; 52(2):75-7. PubMed ID: 9624784
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
    Fawzy A; Vashi V; Chung M; Dias N; Gaffney M
    Urology; 1999 Feb; 53(2):329-35. PubMed ID: 9933049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of hepatic impairment on the pharmacokinetics of doxazosin.
    Penenberg D; Chung M; Walmsley P; Vashi V
    J Clin Pharmacol; 2000 Jan; 40(1):67-73. PubMed ID: 10631624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
    Kaplan SA; Meade-D'Alisera P; Quiñones S; Soldo KA
    Urology; 1995 Oct; 46(4):512-7. PubMed ID: 7571220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
    Chung M; Vashi V; Puente J; Sweeney M; Meredith P
    Br J Clin Pharmacol; 1999 Nov; 48(5):678-87. PubMed ID: 10594469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
    Vashi V; Chung M; Hilbert J; Lawrence V; Phillips K
    J Clin Pharmacol; 1998 Nov; 38(11):1072-6. PubMed ID: 9824790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension: the Japan Morning Surge-1 Study.
    Kario K; Matsui Y; Shibasaki S; Eguchi K; Ishikawa J; Hoshide S; Ishikawa S; Kabutoya T; Schwartz JE; Pickering TG; Shimada K;
    J Hypertens; 2008 Jun; 26(6):1257-65. PubMed ID: 18475166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A LC-MS-MS method for determination of low doxazosin concentrations in plasma after oral administration to dogs.
    Erceg M; Cindric M; Pozaic Frketic L; Vertzoni M; Cetina-Cizmek B; Reppas C
    J Chromatogr Sci; 2010 Feb; 48(2):114-9. PubMed ID: 20109288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
    Kaplan SA; Soldo KA; Olsson CA
    Eur Urol; 1995; 28(3):223-8. PubMed ID: 8536776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Chapman N; Chang CL; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Circulation; 2008 Jul; 118(1):42-8. PubMed ID: 18559700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure-lowering effect and duration of action of bedtime administration of doxazosin determined by home blood pressure measurement.
    Gonokami K; Obara T; Kobayashi M; Katada S; Hara A; Metoki H; Asayama K; Kikuya M; Ohkubo T; Imai Y
    Clin Exp Hypertens; 2010; 32(5):311-7. PubMed ID: 20662733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study.
    Shibasaki S; Eguchi K; Matsui Y; Ishikawa J; Hoshide S; Ishikawa S; Kabutoya T; Pickering TG; Shimada K; Kario K;
    J Hypertens; 2009 Jun; 27(6):1252-7. PubMed ID: 19462498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
    Ahtoy P; Chrétien P; Dupain T; Rauch C; Rouchouse A; Delfolie A
    Int J Clin Pharmacol Ther; 2002 Jul; 40(7):289-94. PubMed ID: 12139205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardura XL--a unique drug formulation--doxazosine administered in a slow-release form (doxazosine GITS)].
    Grzeszczak W
    Przegl Lek; 2000; 57(11):643-54. PubMed ID: 11293213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin.
    Meredith PA; Elliott HL; Kelman AW; Vincent J; Reid JL
    Xenobiotica; 1988 Jan; 18(1):123-9. PubMed ID: 2895548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.